CN101648004A - Medicinal composition for treating eye diseases and application thereof - Google Patents
Medicinal composition for treating eye diseases and application thereof Download PDFInfo
- Publication number
- CN101648004A CN101648004A CN200810118305A CN200810118305A CN101648004A CN 101648004 A CN101648004 A CN 101648004A CN 200810118305 A CN200810118305 A CN 200810118305A CN 200810118305 A CN200810118305 A CN 200810118305A CN 101648004 A CN101648004 A CN 101648004A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- collagen protein
- collagen
- radix
- xerophthalmia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicinal composition for treating syndrome in front of screens, visual fatigue and dry eye syndrome and application thereof, and belongs to the field of Chinese medicament.The raw material medicament of effective components of the medicinal composition is collagen which can be combined with effective components of the Chinese medicament to form various eye preparations.The technical scheme creatively applies the collagen in the eye preparations so as to enlarge the application range of the collagen and achieve remarkable effect in the aspect of treating the syndrome in front of screens, the visual fatigue and the dry eye syndrome.
Description
Technical field
The present invention relates to a kind of medical composition and its use that is used for the treatment of front screen syndrom, asthenopia, xerophthalmia, belong to the field of Chinese medicines.
Background technology
In present communication society, video display terminal (vdt)s such as computer, television set, game machine have been penetrated into each part of our daily life, the thing followed is that front screen syndrom, asthenopia, xerophthalmia patient are more and more, and has become a class social problem.Asthenopia is the common a kind of disease of present ophthalmology, and patient's symptom is varied, and the common near work that has can not be lasting, go out to lose face and eye socket around pain, blurred vision, eyes dry and astringent, shed tears etc., the severe patient headache, feel sick, dizzy.It is not a disease independently, but because one group of fatigue syndrome that a variety of causes causes.Front screen syndrom is meant that point of fixation frequently moves owing to watch fluorescent screen for a long time attentively, film flicker, and keep a kind of operation posture, patient often to feel headache, blurred vision, ocular pain and dry and astringent for a long time.In present communication society, video display terminal (vdt)s such as computer, television set, game machine have been penetrated into each part of our daily life, and have become a class social problem, more and more cause people's attention.Xerophthalmia is one of common eye surface diseases, is meant because the unstable and eye table infringement of tear film unusual or that tear hydrodynamics causes unusually of the quality and quantity of tear, thereby causes a class disease of ophthalmic uncomfortable symptom.Its symptom be usually expressed as sensation of dryness, foreign body sensation, burn feeling, gargalesthesia, blurred vision, furious, corneal contact lens does not tolerate etc.Front screen syndrom, asthenopia, xerophthalmia have common symptom: blurred vision, eyes are dry and astringent and pain etc.
Collagen protein is to contain peptide matters by the skin of animal, bone or heel string through what hydrolysis or enzymolysis mode made, be to form animal connective tissue's important protein matter, connective tissue is except containing 60～70% moisture, collagen protein has accounted for about 20～30%, be the extracellular matrix components that body weight for humans is wanted, have good fibre-forming performance, anthemorrhagic performance, cell-cell interaction performance, promote good biological characteristicses such as wound healing and tissue repair; Pair cell, tissue and even organ exercise normal function and reparation has significant impact to wound, the bootable epithelial cell defective region of moving into, lubricate when cell migration; Be the synthetic substrate of utilizing of regenerative cell, the AC effect is arranged simultaneously, strengthen the regenerative cell adhesive attraction; Collagen between the filling regenerative cell can reduce the auxocyte contact inhibition.As ideal organizational project biomaterial, collagen protein is applied in cosmetics and the hemostasis class medical apparatus and instruments always.New discovers, peptide constituents in the collagen protein has the nutrition of better increase eye, increases the moistening function of ocular surface, can alleviate blurred vision, eyes are dry and astringent and multiple efficacies such as pain, have vast potential for future development in treatment front screen syndrom, asthenopia, xerophthalmia.
In the patent application of collagen eye drops in (application number CN200510098424.7) and the composite collagen eye drops patent application in (application number CN200510098425.1), the not clear and definite effective component group of its applied collagen protein, but according to the preparation method of collagen protein in the patent as can be known, on the patent collagen protein of indication actual be collagen.(will be very big. collagen and collagen protein. Beijing: Chemical Industry Press, 2006.3, clearly defined collagen and collagen protein in this book, and the preparation method of collagen, collagen protein is also had detailed description).As seen collagen protein is particularly treated in front screen syndrom, asthenopia, the xerophthalmia and is used not at ophthalmology.
In view of good lubrication, the Nutrition of collagen protein, be necessary collagen protein is developed to the medicine of treatment front screen syndrom, asthenopia, xerophthalmia.
Summary of the invention
First purpose of the present invention is to provide a kind of pharmaceutical composition for the treatment of front screen syndrom, asthenopia, xerophthalmia.
Second purpose provides the application of this pharmaceutical composition aspect treatment front screen syndrom, asthenopia, xerophthalmia.
Specifically:
The invention provides a kind of pharmaceutical composition for the treatment of front screen syndrom, asthenopia, xerophthalmia, contain collagen protein in this pharmaceutical composition effective ingredient.
Further, this pharmaceutical composition raw materials of effective components medicine is any or the combination more than two kinds in collagen protein and the following Chinese medicine: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Radix Notoginseng, the Radix Paeoniae Alba, Radix Paeoniae Rubra, Flos Carthami, Caulis Spatholobi, Herba Leonuri, Radix Achyranthis Bidentatae, Hirudo, Eupolyphaga Seu Steleophaga, Semen Persicae, Semen Cassiae, Rhizoma Curcumae, Radix Glycyrrhizae, Semen Celosiae, Flos Buddlejae, Cortex Moutan, Semen Oroxyli, Spica Prunellae, Scorpio, Scolopendra, Concha Haliotidis, Calamina, artificial Moschus, Margarita, Margarita layer powder, Borneolum Syntheticum, Mentholum.Collagen protein in this pharmaceutical composition effective ingredient can replace with collagen, or replaces with the mixture of collagen and collagen protein.
The ratio of collagen protein and Chinese medicine ingredients is 1: 0.3～1: 10 in the pharmaceutical composition effective ingredient of the present invention.Wherein middle pharmaceutically active ingredient mean Chinese crude drug after extracting resulting Chinese medicine extract and (or) the former powder of medical material, be meant the ratio of the two solid content weight in the final products with the part by weight of collagen protein.Through preferred, the ratio of collagen protein and Chinese medicine ingredients is 1: 0.1～1: 30 in the pharmaceutical composition effective ingredient, and further the ratio of collagen protein and Chinese medicine ingredients is 1: 1～1: 10 in the preferred pharmaceutical compositions effective ingredient.
The above-mentioned selected medical material of respectively distinguishing the flavor of can be used as medicine by former powder in preparation medicine process of the present invention, also can select suitable method to extract according to the exclusive physicochemical property of effective ingredient, and is refining, obtains corresponding extract and feeds intake.Can pass through extraction as medical materials such as Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Radix Notoginseng, the Radix Paeoniae Alba, Radix Paeoniae Rubra, Flos Carthami, Caulis Spatholobi, Herba Leonuri, Radix Achyranthis Bidentatae, Hirudo, Eupolyphaga Seu Steleophaga, Semen Persicae, Semen Cassiae, Rhizoma Curcumae, Radix Glycyrrhizae, Semen Celosiae, Flos Buddlejae, Cortex Moutan, Semen Oroxyli, Spica Prunellae, Scorpio, Scolopendra, Concha Haliotidis, Calamina, Margarita, Margarita layer powder and obtain the extracting solution application, and medical materials such as artificial Moschus, Borneolum Syntheticum, Mentholum can porphyrize or the directly application of dissolving back.
As everyone knows, collagen protein is the important component part of animal connective tissue, account for 20～30%, so the used collagen protein of the present invention is mainly by raw material processing gained such as gelatin, Colla Corii Asini, new Colla Corii Asini, Corii Sus domestica, Corii Bovis seu Bubali, Os Sus domestica, Os Bovis seu Bubali, pig heel string or cattle heel strings.Above-mentioned raw materials obtains collagen after washing, remove impurity, acidolysis, collagen is meant the spirality fiber shape protein that is twisted into by three peptide chains, is to form animal connective tissue's important protein matter, and its relative molecular weight is 250～300kD, has triple-helix structure; The further hydrolysis of collagen gets gelatin, and its relative molecular weight is 100～200kD, and triple-helix structure is destroyed; Collagen protein is the further enzymatic hydrolysate of gelatin, and its relative molecular weight is below 100kD, and wherein the overwhelming majority exists with the form of collagen peptide, and relative molecular weight is below 10kD.Collagen protein can also be directly from raw materials such as gelatin, Colla Corii Asini, new Colla Corii Asini enzymolysis obtain.The relative molecular weight of collagen and gelatin is big, poorly water-soluble, and the viscosity height, the mechanical strength height, and the relative molecular weight of collagen protein is less, and contained collagen peptide is more, and water solublity is strong, is easy to be absorbed by the body.
At the characteristics of ophthalmic remedy, used collagen protein is the part that molecular weight is not higher than 100kD among the present invention, adopts molecular weight not to be higher than the part of 10kD after preferred, and more preferably molecular weight is not higher than the part of 5kD.
The used collagen protein main preparation methods of the present invention is: gets the collagen protein raw material, cleans, remove impurity such as fat, epidermis, residual meat, adopt acid solution to carry out extract at low temperature, and brine wash, the dialysis remove impurity, enzyme-added enzymolysis is further purified, promptly.
Or rather, the primary raw material of the used collagen protein of the present invention derives from gelatin, Colla Corii Asini, new Colla Corii Asini, Corii Sus domestica, Corii Bovis seu Bubali, Os Sus domestica, Os Bovis seu Bubali, during pig heel string or cattle are followed any one or a few, make through enzymatic isolation method, its relative molecular weight is preferably below the 100kD, described enzyme solution can be a trypsin, pancreatin, neutral protease, alkaline protease, bromelain, any one single enzyme enzymolysis in ficin or the papain, it also can be pepsin, trypsin, pancreatin, neutral protease, alkaline protease, bromelain, the combination enzymolysis of any several enzymes in ficin or the papain, can also be that the bionic enzymatic method of copying the human consumption absorption process fully (promptly at first adopts the pepsin enzymatic isolation method of simulation human stomach's digestion process and physical and chemical parameter, simulate human body intestinal canal then and digest and assimilate the pancreas of process and physical and chemical parameter (albumen) enzyme enzymatic isolation method, thereby obtain to supply the directly low molecule oligopeptide material of absorption of human body).
Among the preparation technology of above-mentioned collagen protein or collagen, used acid is any one or a few in tartaric acid, malic acid, acetic acid, citric acid, glycine or the hydrochloric acid.
Pharmaceutical composition of the present invention mainly adopts the method for being prepared as follows to make:
A, get selected Chinese crude drug, pulverize, adopt water carry/alcohol extraction/first alcohol extraction again water carry/first water is proposed alcohol extraction again/stay, and powder/directly the method for dissolving/extraction volatile oil makes drug extract;
B, get the collagen solution or the fine powder that make, add the said medicine extract, add suitable ophthalmology pharmaceutic adjuvant, make required dosage form according to the pharmaceutics routine techniques, as eye drop, gel for eye use, instant gel for eye, eye ointment, eye patch, eye with ophthalmic preparations such as powder and membrane.
In addition, for improving the preparation curative effect, better bring into play the combination of Chinese medicine and collagen protein, pharmaceutical composition of the present invention can add the Aloe gel with lubrication, can also add the material that has the increase stickiness, lubricates and prolong the drug release time effect, as: Aloe gel, hypromellose, carboxymethyl cellulose, hyaluronate sodium, trehalose, polyvinyl alcohol, poly-interior olefin(e) acid, carbomer, polyvinylpyrrolidone, chitosan etc.
Beneficial effect
As in the above-mentioned summary of the invention state that the present invention makes full use of nutrition, the lubrication of collagen protein, symptoms such as, sufferings dry and astringent for the eyes of alleviating front screen syndrom, asthenopia, xerophthalmia patient, scorching hot, fatigue play good therapeutical effect.
The specific embodiment
Below further specify the present invention by specific embodiment, but following examples only are used to the present invention is described without limits to the present invention.
Embodiment one:
Prescription: collagen protein extracting solution 300ml (containing collagen protein 3.0g)
Method for making: get hyaluronate sodium 0.5g, adding water for injection 600ml profit opened 24 hours, add collagen liquid 300ml, boric acid 12g, Borax 0.6g, ethyl hydroxybenzoate 0.8g, stir to clarify, be heated to 70 ℃, filter, add the injection water to 1000g, cross microporous filter membrane (0.22 μ m), aseptic subpackaged, promptly.(annotate: used collagen protein be gelatin through pepsin and pancreatin bionic enzymatic, again through 5kD the ultrafilter membrane ultrafiltration obtain)
Embodiment two:
Prescription: collagen extracting solution 100ml (containing collagen 30mg) collagen protein extracting solution 200ml (containing collagen protein 2.0g)
Method for making: get water for injection 1600ml, add gellan gum, stir, put in the boiling water bath, stir to clarify, add boric acid 24g, Borax 1.2g, ethyl hydroxybenzoate 1.2g, be heated to 70 ℃, stir to clarify, filter, stir adding collagen extracting solution, collagen protein extracting solution down, add the injection water to 2000g, cross microporous filter membrane (0.22 μ m), aseptic subpackaged, promptly.(annotate: used collagen protein be Corii Sus domestica through neutral protease enzymolysis, again through 10kD the ultrafilter membrane ultrafiltration obtain, collagen is raw material with the Corii Bovis seu Bubali, adopts acetic acid solution to extract, and makes through the pepsin enzymolysis, relative molecular weight is at 250～285kD.)
Embodiment three:
Prescription: Radix Paeoniae Rubra 500g aloe gel 20:1 g Mentholum 0.5g
Collagen protein extracting solution 200ml (containing collagen protein 2g)
Method for making: get Radix Paeoniae Rubra, add 8 times of water gagings and decoct twice, each 2 hours, filter merging filtrate, concentrating under reduced pressure, adding ethanol makes and contains alcohol amount and reach 70%, standing over night is got the supernatant decompression recycling ethanol, AB-8 macroporous adsorptive resins on the surplus water liquid, respectively with water, 50% ethanol elution, collect 50% ethanol elution, decompression recycling ethanol is not to there being the alcohol flavor, and water liquid is standby; Other gets phenoxyethanol and joins 1000ml and be heated in about 80 ℃ water for injection, stirs evenly, and adds boric acid 24g while hot, Borax 1.2g, stirring makes dissolving, put coldly, join in the Radix Paeoniae Rubra extracting solution, stir evenly, slowly add Aloe gel, the Mentholum of dissolve with ethanol, continue to be stirred to dissolving fully, add the collagen protein extracting solution, and add the injection water to 2000ml, crossing microporous filter membrane (0.22m) filters, filtrate reheat to 50 ℃, add while hot hypromellose (50000～70000mpas), be stirred to room temperature, add the injection water to 2000g, stir evenly, form even gel, filter (0.80 μ m), aseptic subpackaged, promptly.(annotate: used collagen protein be Corii Sus domestica and heel string through pepsin and papain enzymolysis, again through 100kD the ultrafilter membrane ultrafiltration obtain)
Embodiment four:
Prescription: Margarita liquid 60ml Mentholum 0.5g collagen protein 1.5g
Method for making: get Margarita powder, add 4 times of amount 10% sulfuric acid solutions, heated 2 hours, filter, filtrate adds calcium oxide and transfers to neutrality, filters, and gets Margarita liquid (contain total protein concentration and be not less than 1mg/ml); Get among gellan gum 8g and boric acid, the Borax adding water for injection 1800ml, heated and boiled is cooled to 80 ℃, add Margarita liquid 60ml, be cooled to 60 ℃ while stirring, in addition Mentholum 0.5g, ethyl hydroxybenzoate 1g are dissolved in the ethanol, be added dropwise to while stirring in the above solution, add collagen protein again, stir and make dissolving, and add the injection water to 2000ml, stir more than 30 minutes, cross microporous filter membrane (0.22 μ m), aseptic subpackaged, promptly.(annotate: used collagen protein be Os Sus domestica and pig heel string through the alkaline protease enzymolysis, again through 5kD the ultrafilter membrane ultrafiltration obtain)
Embodiment five:
Prescription: Concha Haliotidis 200g Flos Buddlejae 200g Borneolum Syntheticum 2g
Collagen protein extracting solution 200ml (containing collagen protein 4g)
Collagen extracting solution 100ml (containing collagen 20mg)
Method for making: get Flos Buddlejae, add 10 times of water gagings, steam distillation extracts volatile oil, collects distillate 600ml, and is standby; Get Concha Haliotidis, be ground into fine powder, it is even to add 10 times of water gaging suspendibles, regulate Ph6.0, add 1% papain, 60 ℃ of water-bath hydrolysis 6 hours, filter, add boric acid, Borax, add phenoxyethanol 2g, stir evenly, stir adding vapor distillation liquid down, get Borneolum Syntheticum again with dissolve with ethanol, add under stirring in the above-mentioned mixed liquor, add the collagen protein extracting solution, add the injection water again to 3000ml, cross microporous filter membrane (0.22 μ m), aseptic subpackaged, promptly.(annotate: used collagen protein be Colla Corii Asini through trypsin digestion, again through 5kD the ultrafilter membrane ultrafiltration obtain, collagen is raw material with the Os Bovis seu Bubali, adopts citric acid solution to extract, and makes through papain enzymolysis, relative molecular weight is at 260～290kD.)
Embodiment six:
Prescription: Calamina 32.7g artificial Moschus 0.38g artificial Calculus Bovis 0.38g
Margarita 0.38g Borneolum Syntheticum 14.8g Borax 1.2g
Collagen protein 2g
Method for making: above seven flavors, Calamina, Margarita, Borax pulverize separately become impalpable powder; Artificial Moschus, artificial Calculus Bovis, Borneolum Syntheticum, collagen protein be porphyrize respectively; with above-mentioned powder facing-up; sieve; join after sterilization, filtration and put among the cold liquid paraffin 20g; stir evenly; join dry heat sterilization again, filter and be chilled to stir evenly among about 50 ℃ vaseline 890g and the lanoline 40g and solidify, promptly.(annotate: used collagen protein be new Colla Corii Asini through pepsin and trypsin bionic enzymatic, again through 3kD the ultrafilter membrane ultrafiltration obtain)
Embodiment seven:
Prescription: Pulvis Fellis Suis 2g Pulvis Cornus Bubali Concentratus 10g Margarita 20g
Borneolum Syntheticum 2g collagen protein 5g
Method for making: the above five tastes, mix, comminution by gas stream is crossed sieve No. nine, sterilization, promptly.(annotate: used collagen protein be Corii Bovis seu Bubali and cattle heel string through papain enzymolysis, again through 3kD the ultrafilter membrane ultrafiltration obtain)
Embodiment eight:
Prescription: artificial Moschus 1g Margarita layer powder 20g collagen protein 3g
Method for making: get Margarita layer powder, hydrolysis gets Margarita layer powder hydrolysate 20ml, crosses microporous filter membrane (0.22 μ m), and is standby; Get polyvinyl alcohol 30g, glycerol 5g, add in the 50ml water for injection, be dipped to fully and run through, to water-bath, be heated to 80 ℃ of dissolvings, promptly get filmogen stock solution; Other gets artificial Moschus and collagen protein, adds injection water 20ml and makes dissolving, adds Margarita layer powder hydrolysate again, mixing adds in the above-mentioned filmogen stock solution, stirs evenly, put 80 ℃ of water bath heat preservation 30min, pour into again on the glass plate (smearing with liquid paraffin in advance), the about 2000cm of manual system film
2, 80 ℃ of forced air dryings, demoulding takes out the 45min that sterilizes under uviol lamp immediately, cuts fritter, and aseptic packaging is promptly.(annotate: used collagen protein be gelatin through bionic enzymatic, again through 3kD the ultrafilter membrane ultrafiltration obtain)
Embodiment nine:
Prescription: Margarita 20g glycyrrhizic acid dipotassium 1g collagen protein extracting solution 20ml (containing collagen protein 5g)
Method for making: get Margarita, powder is to fine powder, and heating hydrolysis gets Margarita hydrolyzed solution 20ml; Collagen protein extracting solution and Margarita hydrolyzed solution are mixed, add glycyrrhizic acid dipotassium, add hydroxyethyl methylacrylate, ethylene glycol, grind well, add 12% ammonium persulfate solution and 24% sodium metasulfite solution again, fully grind well, get the 5ml mixed liquor respectively in evaporating dish, place 37 ℃ of thermostatic water-circulator bath pot 3h.Take out, washing be placed on 4 ℃ standby.(annotate: used collagen protein be Corii Sus domestica and Corii Bovis seu Bubali through bionic enzymatic, again through 100kD the ultrafilter membrane ultrafiltration obtain)
Embodiment ten:
Get embodiment three gained gel for eye treatment xerophthalmia and examine patient's 47 examples, wherein male 11 examples, women 36 examples, 28～58 years old age; The course of disease 1 month to 3 years; Be the eyes morbidity, totally 94 eyes, wherein computation work causer 16 examples, trachoma paralysis trace causer 6 examples, alkali burn causer 3 examples, causer 9 examples such as rheumatoid arthritis and lupus erythematosus disease, dermatosis, wear contact lenses causer 7 examples, sjogren syndrome causer 6 examples.4 times/d of administration, 1～2 droplet/time, 30 days is a course of treatment, observes after 2 courses of treatment.Cure 20 eyes (transference cure, corneal dyeing reduce, the Schirmer test repeatedly measure greater than 10mm＞/5min), 49 eyes that take a turn for the better (sx, corneal dyeing reduces, Schirmer tests and repeatedly measures the lacrimal secretion amount and increase to some extent); Invalid 25 eyes (symptom does not have improvement, corneal dyeing no change or increase, the secretion that tear is repeatedly measured in the Schirmer test does not increase), effective percentage 79.5%.
Embodiment 11:
Get embodiment one gained eye drop treatment asthenopia patient 143 examples, male 82 examples, women 61 examples, 18～65 years old age, average 31.4 years old.Ophthalmic bloated 88 examples ((68.5%), blurred vision 78 examples (54.5%), xerophthalmia scheorma 71 examples (49.7%), upper eyelid sense of heaviness 64 examples (44.8%), dizzy 52 examples (39.8%), photophobia 28 examples (19.5%), ophthalmalgia 21 examples (14.7%) wherein; Fibroplasia 132 examples (92.3%) behind the corneal epithelium are shown in inspection, and conjunctiva mild hyperaemia 87 examples (60.8%) are the eyes morbidity.4 times/d of eye dripping, check after 2 months.As a result, the subjective sensation of ophthalmic uncomfortable all has alleviating in various degree, fibroplasia 121 examples that disappear behind the corneal epithelium, (84.6%), and discomfort alleviates 22 examples (15.4%), and conjunctiva mild hyperaemia sill disappears, total effective rate 100%; Vision, intraocular pressure sill do not change.
Claims (10)
1, a kind of pharmaceutical composition that is used for the treatment of front screen syndrom, asthenopia, xerophthalmia is characterized in that containing collagen protein in this pharmaceutical composition effective ingredient.
2, a kind of front screen syndrom that is used for the treatment of, asthenopia, the pharmaceutical composition of xerophthalmia is characterized in that this pharmaceutical composition raw materials of effective components medicine is any or the combination more than two kinds in collagen protein and the following Chinese medicine: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Radix Notoginseng, the Radix Paeoniae Alba, Radix Paeoniae Rubra, Flos Carthami, Caulis Spatholobi, Herba Leonuri, Radix Achyranthis Bidentatae, Hirudo, Eupolyphaga Seu Steleophaga, Semen Persicae, Semen Cassiae, Rhizoma Curcumae, Radix Glycyrrhizae, Semen Celosiae, Flos Buddlejae, Cortex Moutan, Semen Oroxyli, Spica Prunellae, Scorpio, Scolopendra, Concha Haliotidis, Calamina, the artificial Moschus, Margarita, Margarita layer powder, Borneolum Syntheticum, Mentholum.
3, pharmaceutical composition according to claim 2 is characterized in that the ratio of collagen protein and Chinese medicine ingredients is 1: 0.1～1: 30 in this pharmaceutical composition effective ingredient.
4, pharmaceutical composition according to claim 2 is characterized in that the ratio of collagen protein and Chinese medicine ingredients is 1: 1～1: 10 in this pharmaceutical composition effective ingredient.
5,, it is characterized in that collagen protein wherein replaces with collagen, or replace with the mixture of collagen and collagen protein according to each described pharmaceutical composition of claim 2 to 4.
6, according to each described pharmaceutical composition of claim 1 to 4, it is characterized in that used collagen protein is to be made through enzymolysis by gelatin, Colla Corii Asini, new Colla Corii Asini, Corii Sus domestica, Corii Bovis seu Bubali, Os Sus domestica, Os Bovis seu Bubali, pig heel string or cattle heel string, its relative molecular weight is not higher than 10kD.
7, pharmaceutical composition according to claim 6 is characterized in that the relative molecular weight of used collagen protein is not higher than 5kD
8, pharmaceutical composition according to claim 5 is characterized in that used collagen is to be made by Corii Sus domestica, Corii Bovis seu Bubali, Os Sus domestica, Os Bovis seu Bubali, pig heel string or cattle heel string, and its relative molecular weight is 250～300kD.
9, each described pharmaceutical composition is used for the treatment of application in the medicine of front screen syndrom, asthenopia, xerophthalmia in preparation in the claim 1 to 8.
10, collagen protein is used for the treatment of application in the medicine of front screen syndrom, asthenopia, xerophthalmia in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101183057A CN101648004B (en) | 2008-08-13 | 2008-08-13 | Medicinal composition for treating eye diseases and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101183057A CN101648004B (en) | 2008-08-13 | 2008-08-13 | Medicinal composition for treating eye diseases and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101648004A true CN101648004A (en) | 2010-02-17 |
| CN101648004B CN101648004B (en) | 2013-11-06 |
Family
ID=41670402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101183057A Expired - Fee Related CN101648004B (en) | 2008-08-13 | 2008-08-13 | Medicinal composition for treating eye diseases and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101648004B (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102648968A (en) * | 2011-02-26 | 2012-08-29 | 晏素琼 | External traditional Chinese medicine composition for eye health |
| CN103041067A (en) * | 2013-01-27 | 2013-04-17 | 袁琳 | Traditional Chinese medicine for treating xerophthalmia |
| CN103083546A (en) * | 2013-02-23 | 2013-05-08 | 盛翔 | Method for processing condensed pill for regaining sight |
| CN103520392A (en) * | 2013-10-08 | 2014-01-22 | 广州加原医药科技有限公司 | Traditional Chinese medicine composition for treating xerophthalmia and preparation method thereof |
| CN104274600A (en) * | 2013-07-03 | 2015-01-14 | 郑州市新视明科技工程有限公司 | New application of traditional Chinese medicinal composition |
| CN104274601A (en) * | 2013-07-03 | 2015-01-14 | 郑州市新视明科技工程有限公司 | External traditional Chinese medicinal composition for treating xerophthalmia and preparation method thereof |
| CN104367810A (en) * | 2014-11-19 | 2015-02-25 | 济南伟传信息技术有限公司 | Traditional Chinese medicine decoction for relieving visual fatigue |
| CN104383229A (en) * | 2014-12-06 | 2015-03-04 | 邹士东 | Traditional Chinese medicine composition for treating yin deficiency and yang excess type xerophthalmia |
| CN104435651A (en) * | 2014-11-19 | 2015-03-25 | 济南伟传信息技术有限公司 | Traditional Chinese medicine for protecting eyes and relieving visual fatigue |
| CN104474509A (en) * | 2014-12-02 | 2015-04-01 | 周南燕 | Medicine patch for conditioning eye refraction and preparation method of medicine patch |
| CN108175950A (en) * | 2018-01-22 | 2018-06-19 | 陈宇甦 | A kind of fever eye treatment device |
| CN111420036A (en) * | 2020-04-30 | 2020-07-17 | 广州市醒目医药科技有限公司 | Compound containing type I collagen and salvia miltiorrhiza extract, preparation and application |
| CN111603500A (en) * | 2020-06-30 | 2020-09-01 | 河南中大恒源生物科技股份有限公司 | Semen cassiae extract and process technology for comprehensively developing and utilizing semen cassiae |
| CN113713086A (en) * | 2021-08-20 | 2021-11-30 | 山西锦波生物医药股份有限公司 | Composition containing recombinant III-type humanized collagen and preparation method and application thereof |
| CN114246879A (en) * | 2021-12-30 | 2022-03-29 | 沈阳兴齐眼药股份有限公司 | Application of oroxin B in preparation of medicine for preventing, controlling and/or treating eye diseases |
| CN114748611A (en) * | 2022-03-14 | 2022-07-15 | 深圳中科欣扬生物科技有限公司 | Composition with antioxidant, moisturizing and lubricating effects and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100381169C (en) * | 2005-09-08 | 2008-04-16 | 佟刚 | Composite collagen eye drops |
| CN1813669A (en) * | 2005-12-07 | 2006-08-09 | 陕西博森生物制药股份集团有限公司 | Wrinkle-removing eye paster and method for preparing its product |
| CN101130066A (en) * | 2007-07-24 | 2008-02-27 | 李立 | Segmented intestine targeted preparation of animal skin glue collagen polypeptide and method of preparing the same |
-
2008
- 2008-08-13 CN CN2008101183057A patent/CN101648004B/en not_active Expired - Fee Related
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102648968A (en) * | 2011-02-26 | 2012-08-29 | 晏素琼 | External traditional Chinese medicine composition for eye health |
| CN102648968B (en) * | 2011-02-26 | 2013-12-18 | 晏素琼 | External traditional Chinese medicine composition for eye health |
| CN103041067B (en) * | 2013-01-27 | 2014-04-09 | 袁琳 | Traditional Chinese medicine for treating xerophthalmia |
| CN103041067A (en) * | 2013-01-27 | 2013-04-17 | 袁琳 | Traditional Chinese medicine for treating xerophthalmia |
| CN103083546B (en) * | 2013-02-23 | 2014-04-30 | 盛翔 | Method for processing condensed pill for regaining sight |
| CN103083546A (en) * | 2013-02-23 | 2013-05-08 | 盛翔 | Method for processing condensed pill for regaining sight |
| CN104274601B (en) * | 2013-07-03 | 2017-12-12 | 郑州市新视明科技工程有限公司 | A kind of Chinese medicine composition of external curing xerophthalmia and preparation method thereof |
| CN104274600A (en) * | 2013-07-03 | 2015-01-14 | 郑州市新视明科技工程有限公司 | New application of traditional Chinese medicinal composition |
| CN104274601A (en) * | 2013-07-03 | 2015-01-14 | 郑州市新视明科技工程有限公司 | External traditional Chinese medicinal composition for treating xerophthalmia and preparation method thereof |
| CN104274600B (en) * | 2013-07-03 | 2017-12-29 | 郑州市新视明科技工程有限公司 | A kind of new application of Chinese medicine composition |
| CN103520392A (en) * | 2013-10-08 | 2014-01-22 | 广州加原医药科技有限公司 | Traditional Chinese medicine composition for treating xerophthalmia and preparation method thereof |
| CN103520392B (en) * | 2013-10-08 | 2015-09-09 | 广州加原医药科技有限公司 | A kind of Chinese medicine composition for the treatment of xerophthalmia and preparation method thereof |
| CN104367810A (en) * | 2014-11-19 | 2015-02-25 | 济南伟传信息技术有限公司 | Traditional Chinese medicine decoction for relieving visual fatigue |
| CN104435651A (en) * | 2014-11-19 | 2015-03-25 | 济南伟传信息技术有限公司 | Traditional Chinese medicine for protecting eyes and relieving visual fatigue |
| CN104474509A (en) * | 2014-12-02 | 2015-04-01 | 周南燕 | Medicine patch for conditioning eye refraction and preparation method of medicine patch |
| CN104383229A (en) * | 2014-12-06 | 2015-03-04 | 邹士东 | Traditional Chinese medicine composition for treating yin deficiency and yang excess type xerophthalmia |
| CN108175950A (en) * | 2018-01-22 | 2018-06-19 | 陈宇甦 | A kind of fever eye treatment device |
| CN111420036A (en) * | 2020-04-30 | 2020-07-17 | 广州市醒目医药科技有限公司 | Compound containing type I collagen and salvia miltiorrhiza extract, preparation and application |
| CN111603500A (en) * | 2020-06-30 | 2020-09-01 | 河南中大恒源生物科技股份有限公司 | Semen cassiae extract and process technology for comprehensively developing and utilizing semen cassiae |
| CN111603500B (en) * | 2020-06-30 | 2022-03-04 | 河南中大恒源生物科技股份有限公司 | Semen cassiae extract and process technology for comprehensively developing and utilizing semen cassiae |
| CN113713086A (en) * | 2021-08-20 | 2021-11-30 | 山西锦波生物医药股份有限公司 | Composition containing recombinant III-type humanized collagen and preparation method and application thereof |
| CN114246879A (en) * | 2021-12-30 | 2022-03-29 | 沈阳兴齐眼药股份有限公司 | Application of oroxin B in preparation of medicine for preventing, controlling and/or treating eye diseases |
| CN114246879B (en) * | 2021-12-30 | 2023-10-27 | 沈阳兴齐眼药股份有限公司 | Use of oroxylin B in preparing medicament for preventing, controlling and/or treating eye diseases |
| CN114748611A (en) * | 2022-03-14 | 2022-07-15 | 深圳中科欣扬生物科技有限公司 | Composition with antioxidant, moisturizing and lubricating effects and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101648004B (en) | 2013-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101648004B (en) | Medicinal composition for treating eye diseases and application thereof | |
| CN101648018A (en) | Medicinal composition for treating ophthalmic inflammation and application thereof | |
| CN101716214B (en) | Medical composition containing dandelion extract as well as novel application and preparation method thereof | |
| CN101648003A (en) | Medicinal composition for treating gynecological inflammation and application thereof | |
| CN101648002A (en) | Medicinal composition for treating skin injury and ulcer and application thereof | |
| CN104225265B (en) | A kind of Traditional Chinese medicine composition for relieving asthenopia | |
| CN101648005A (en) | Medicinal composition for treating skin injury and ulcer and application thereof | |
| CN1066945C (en) | Chinese drug Mingmudan pill for improving eyesight and its producing method | |
| CN102813780A (en) | Chinese herbal medicinal compound preparation used for treating macular degeneration of old people and preparation method thereof | |
| CN102000278A (en) | Traditional Chinese medicine for treating amblyopia eye diseases | |
| CN104971304A (en) | Xerophthalmia treatment medicine | |
| CN101648015A (en) | Chinese medicinal composition for treating glaucoma and application thereof | |
| CN110327401A (en) | Treat amblyopia and the Chinese medicinal plaster of myopia and preparation method thereof | |
| CN109865016A (en) | A kind of pharmaceutical composition and its preparation method and application for treating xerophthalmia | |
| CN104043038A (en) | Medicinal preparation used for treating early-stage diabetic foot | |
| CN106362089A (en) | External medicine for treating eye diseases | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN105125735A (en) | Traditional Chinese medicinal composition for treating xerophthalmia | |
| CN110101774A (en) | One kind is for treating presbyopic Chinese materia medica preparation of person in middle and old age and preparation method thereof | |
| CN109820890A (en) | A kind of pharmaceutical composition and its preparation method and application with alleviation visual fatigue effect | |
| CN1268354C (en) | Traditional Chinese medicine preparation for treating myopia and method for preparing the same | |
| CN105250394A (en) | Traditional Chinese medicine composition for treating cataract and preparation method and application thereof | |
| CN106491730A (en) | A kind of treat Chinese medicine composition of glaucoma and preparation method thereof | |
| CN106619788A (en) | Pharmaceutical composition for treating cataract, and preparation method of pharmaceutical composition | |
| CN106902344A (en) | It is a kind of to treat Chinese medicine composition of glaucoma and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20151009 Address after: 241000 Anhui Province, Wuhu city Jinghu District long Fang Culture Park (big long Fang No. 77) B01 Building Room 201 Patentee after: ANHUI BIOLOGICAL PEPTIDE INDUSTRY RESEARCH INSTITUTE Address before: 100022, 1902, Jianguo Road, C building, 98 Jianguo Road, Beijing, Chaoyang District Patentee before: Beijing Herun Chuangxin Pharmaceutical Technology Development Co., Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160714 Address after: 239300 Xicheng District Industrial Park, Anhui, Tianchang Patentee after: Anhui Province Huading Biotechnology Co., Ltd. Address before: 241000 Anhui Province, Wuhu city Jinghu District long Fang Culture Park (big long Fang No. 77) B01 Building Room 201 Patentee before: ANHUI BIOLOGICAL PEPTIDE INDUSTRY RESEARCH INSTITUTE |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131106 Termination date: 20160813 |